Guardant Health Announces Reimbursement Approval Of Guardant360 CDX Liquid Biopsy Test In Japan
Portfolio Pulse from Happy Mohamed
Guardant Health, Inc. (NASDAQ:GH) has announced that it will receive national reimbursement approval from the Japanese Ministry of Health, Labor and Welfare for its Guardant360 CDx liquid biopsy test for comprehensive genomic profiling for patients with advanced or metastatic solid tumor cancers, effective July 24, 2023. The test has already received regulatory approval in March 2022. The test is used to detect actionable biomarkers in a patient's blood that may help inform their therapy selection.
July 05, 2023 | 12:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guardant Health's Guardant360 CDx liquid biopsy test has received reimbursement approval in Japan, which could lead to increased usage and revenues for the company. The approval is a significant milestone as Japan is the first country in the Asia-Pacific region to reimburse the use of the test.
The reimbursement approval in Japan for Guardant Health's Guardant360 CDx liquid biopsy test is a significant development for the company. This could lead to increased usage of the test in Japan, potentially boosting the company's revenues. Furthermore, as Japan is the first country in the Asia-Pacific region to reimburse the use of the test, this could pave the way for similar approvals in other countries in the region, further expanding the market for the test.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100